Loading…
Esperion Therapeutics Inc is projected to rise to $3.41 by 2027, a +7% move from its current price of $3.18. ESPR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $3.12 | $3.18 | $3.24 | 0.00% |
| Aug 3 | $3.09 | $3.18 | $3.27 | 0.00% |
| Aug 4 | $3.07 | $3.18 | $3.29 | 0.00% |
| Aug 5 | $3.06 | $3.18 | $3.31 | 0.00% |
| Aug 6 | $3.04 | $3.18 | $3.32 | 0.00% |
| Aug 7 | $3.03 | $3.18 | $3.34 | 0.00% |
| Aug 8 | $3.02 | $3.18 | $3.35 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.02 | $3.18 | $3.35 | 0.00% |
| Week 2 | $2.95 | $3.18 | $3.42 | -0.01% |
| Week 3 | $2.90 | $3.18 | $3.48 | -0.01% |
| Week 4 | $2.86 | $3.18 | $3.53 | -0.02% |
| Week 5 | $2.83 | $3.18 | $3.58 | -0.02% |
| Week 6 | $2.80 | $3.18 | $3.62 | -0.02% |
| Week 7 | $2.77 | $3.18 | $3.65 | -0.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Esperion Therapeutics, Inc. is a healthcare biopharmaceutical company that develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C.
The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion was incorporated in 2008 and was formerly known as HDL Therapeutics, Inc., and is headquartered in Ann Arbor, Michigan. As of July 13, 2026, Esperion Therapeutics, Inc. was taken private.
Esperion Therapeutics Inc (ESPR) operates in the Healthcare sector with a current price of $3.18. It carries a market cap of $819.46M and holds a rank of 2573. The stock is positioned within a sphere of healthcare-focused therapies aimed at lowering LDL-C levels.
The near-term price outlook is reflected in a forecast that shows a flat to modestly rising trajectory from a 2026 average of $3.18 to higher levels in subsequent years. The forecast provides year-by-year averages, with a clear long-term bullish tilt and substantial ROI growth projected into the 2030s and 2040s.
A major floor 39.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.6% away) — a key level to hold.
Price is pressing into resistance (0.3% away) — a breakout level to watch.
A major ceiling 1.5% above — clearing it would confirm fresh momentum.
Key ESPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ESPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.19 | Sell | $3.18 | Sell |
| MA 10 | $3.17 | Buy | $3.17 | Buy |
| MA 20 | $3.16 | Buy | $3.16 | Buy |
| MA 50 | $3.15 | Buy | $3.06 | Buy |
| MA 100 | $2.86 | Buy | $2.99 | Buy |
| MA 200 | $3.06 | Buy | $2.85 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.48 | Neutral |
| Stoch RSI (14) | 46.89 | Neutral |
| CCI (20) | 87.20 | Neutral |
| Williams %R (14) | -25.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 0.95 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 75.00 | Neutral |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 63.20 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 3.19 | Sell |
| ADX (14) | 34.21 | Buy |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is mixed but leaning bullish. RSI14 is 60, supporting a constructive momentum stance. The stock trades near the SMA50 of $3.12 and above the SMA200 of $3.06, suggesting minor near-term upside bias.
The near-term range spans from a low of $2.79 to a high of $3.62 over the past 30 days, with a near-term support at $3.13 and resistance at $3.19. Annualized volatility is elevated at 40%, indicating meaningful swings in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.91 | $3.18 | $3.85 | 0% | Neutral | |
| $2.79 | $3.41 | $4.37 | +7% | Neutral | |
| $3.19 | $3.99 | $5.26 | +25% | Bullish | |
| $3.45 | $4.38 | $5.90 | +38% | Bullish | |
| $3.97 | $5.11 | $7.02 | +61% | Bullish | |
| $4.29 | $5.60 | $7.81 | +76% | Bullish | |
| $4.28 | $5.65 | $8.00 | +78% | Bullish | |
| $4.56 | $6.09 | $8.74 | +91% | Bullish | |
| $4.60 | $6.21 | $9.02 | +95% | Bullish | |
| $4.97 | $6.77 | $9.96 | +113% | Bullish | |
| $6.92 | $9.86 | $15.23 | +210% | Bullish | |
| $13.11 | $20.13 | $33.41 | +533% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.69 | $3.15 | $3.76 | -0.96% |
| September 2026 | $2.65 | $3.11 | $3.75 | -1.13% |
| October 2026 | $2.69 | $3.18 | $3.86 | +2.07% |
| November 2026 | $2.69 | $3.19 | $3.90 | +0.47% |
| December 2026 | $2.64 | $3.14 | $3.85 | -1.71% |
Click any year to see its month-by-month ESPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ESPR price prediction for 2026 points to an average of $3.18 (low $1.91, high $3.85) — a potential gain of 0% on today's $3.18. A consolidation phase looks the most probable path here.
In 2027, ESPR is projected to trade between $2.79 and $4.37, averaging $3.41 — a potential gain of +7% from today's $3.18. That is up +7% on the projected 2026 average. Price action looks broadly range-bound.
Esperion Therapeutics Inc's 2028 outlook centres on $3.99, within a $3.19 to $5.26 range. That is up +17% on the projected 2027 average. That marks a +25% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ESPR could reach as high as $5.90, with a base case around $4.38 and support toward $3.45 — roughly +38% from $3.18. Momentum favours further upside here.
Expect ESPR to range from $3.97 to $7.02 through 2030. The $5.11 average target implies a +61% move from current prices. That is up +17% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ESPR price prediction for 2031 points to an average of $5.60 (low $4.29, high $7.81) — a potential gain of +76% on today's $3.18. Momentum favours further upside here.
In 2032, ESPR is projected to trade between $4.28 and $8.00, averaging $5.65 — a potential gain of +78% from today's $3.18. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Esperion Therapeutics Inc's 2033 outlook centres on $6.09, within a $4.56 to $8.74 range. That is up +8% on the projected 2032 average. That marks a +91% change versus current levels. Momentum favours further upside here.
By 2034, ESPR could reach as high as $9.02, with a base case around $6.21 and support toward $4.60 — roughly +95% from $3.18. Buyers look set to stay in control over this stretch.
Expect ESPR to range from $4.97 to $9.96 through 2035. The $6.77 average target implies a +113% move from current prices. That is up +9% on the projected 2034 average. Momentum favours further upside here.
The ESPR price prediction for 2040 points to an average of $9.86 (low $6.92, high $15.23) — a potential gain of +210% on today's $3.18. Buyers look set to stay in control over this stretch.
In 2050, ESPR is projected to trade between $13.11 and $33.41, averaging $20.13 — a potential gain of +533% from today's $3.18. That is up +104% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ESPR today (≈ 314.465409 ESPR) could be worth
$6,328.97
+$5,328.97 (+533%) by 2050 · US Dollar
Based on the average projected ESPR price of $20.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ESPRwould be worth at today's price.
$1,000 invested in ESPR on Jul 14, 2025 (≈ 847.457665 ESPR) would be worth
$2,694.92
+$1,694.92 (+169.5%) today · 2.69× · US Dollar
Based on a ESPR entry price of $1.18 vs. today's $3.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.16 | $1,006.33 | +0.6% |
| 1 month ago | $3.15 | $1,009.52 | +1.0% |
| 3 months ago | $2.17 | $1,465.44 | +46.5% |
| 6 months ago | $3.13 | $1,015.97 | +1.6% |
| 1 year ago | $1.18 | $2,694.92 | +169.5% |
| All time (5.0y) ago | $14.99 | $212.14 | -78.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ESPR forecast.
Our base-case forecast reaches $6.40 around 2035.
Implied market cap at $6.40: $1.65B
The multi-year forecast shows a rising average price path and growing ROI across the horizon. In 2026 the avg price is $3.18 with a 0% ROI, transitioning to a 2027 avg of $3.41 and continuing higher thereafter. By 2030 the avg is $5.11 with a 60.8% ROI, and by 2040 the avg rises to $9.86 with a 210.1% ROI.
In 2050 the avg is $20.13 with a 532.9% ROI, and the sentiment is bullish across the later years.
These projections imply a strong long-term appreciation trajectory with notable upside potential, particularly toward the end of the forecast period. However, as with all forecasts, these are estimates, not guarantees, and actual outcomes depend on market conditions, regulatory developments, and multiple external factors.
Tap a question to reveal the answer.
The forecast shows the average price in 2030 at $5.11 with a ROI of 60.8%.
The forecast indicates a bullish path later in the horizon, with 2030-2050 average prices rising to values such as $5.11 (2030) and $20.13 (2050) with rising ROI (e.g., 60.8% in 2030 and 532.9% in 2050). The 2026 average is $3.18 with 0% ROI. These are estimates, not guarantees.
The forecast shows a 2040 average price of $9.86 and a 2050 average price of $20.13, suggesting the possibility of reaching around $10 by 2040, though these are projections and not guarantees.
Market cap is $819.46M and rank is 2573.
Esperion Therapeutics Inc Community Discussion
0Share your Esperion Therapeutics Inc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.